A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia

• Main Authors: Coppola, D., Liu, Y.N., Gopal, S., Remmerie, B., Samtani, M.N., Hough, D.W., Nuamah, I., Sulaiman, A., Pandina, G.
• Format: Article
• Language: English
• Published: BioMed Central 2012
• Subjects: BF Psychology; R Medicine
• Online Access: http://eprints.um.edu.my/10978/1/Coppola-2012-A_one-year_prospecti.pdf; http://eprints.um.edu.my/10978/; http://www.biomedcentral.com/1471-244X/12/26/

Background: There are no previous reports of paliperidone palmitate's (PP) long term tolerability or pharmacokinetics of the highest dose in patients with schizophrenia. This study evaluates safety and tolerability, as well as pharmacokinetics, of the highest marketed dose of PP (150 mg eq. 234...